Dalal Nesheiwat serves as the Vice President and Global Head of Clinical Science at Daiichi Sankyo US, where she plays a pivotal role in steering both early and late-phase research and development (R&D) initiatives within the oncology and hematology domains. With a robust background in...
Dalal Nesheiwat serves as the Vice President and Global Head of Clinical Science at Daiichi Sankyo US, where she plays a pivotal role in steering both early and late-phase research and development (R&D) initiatives within the oncology and hematology domains. With a robust background in Global Clinical Development, Dalal brings a wealth of expertise in regulatory submission management and program leadership, making her an invaluable asset to the organization. Her leadership is characterized by a deep commitment to advancing innovative therapies for patients with hematological malignancies and solid tumors, particularly in the context of rare diseases.
In her current role, Dalal is at the forefront of key projects that aim to revolutionize treatment paradigms, leveraging her extensive knowledge in clinical pharmacology and medical affairs. She adeptly manages collaborations with Contract Research Organizations (CROs), ensuring that clinical trials are executed with precision and adherence to regulatory standards. Dalal's proficiency in scientific writing enhances the clarity and impact of clinical documentation, facilitating smoother regulatory submissions and fostering transparent communication with stakeholders.
Her dependable team player mentality fosters a collaborative environment, empowering cross-functional teams to achieve ambitious clinical objectives. Dalal’s self-confidence and strategic vision not only drive project success but also inspire her colleagues to push the boundaries of scientific inquiry. As the landscape of oncology and hematology continues to evolve, Dalal Nesheiwat remains a dynamic leader, dedicated to transforming patient outcomes through innovative clinical science initiatives at Daiichi Sankyo.
